Thoracic Cancer最新文献

{"title":"Safety and Efficacy of the First Subcutaneous ICI, Envafolimab, in the Treatment of Advanced Lung Cancer Patients: A Real-World Study.","authors":"Zixuan Dou, Li Wang, Meng Rui, Yulong Yang, Yunzhi Zhou, JieLi Zhang, Qiuhong Zhao, Mengzhao Wang, Hanping Wang, Xiaotong Zhang, Xiaoxia Cui, Xiaoyan Si, Li Zhang","doi":"10.1111/1759-7714.70101","DOIUrl":"https://doi.org/10.1111/1759-7714.70101","url":null,"abstract":"<p><strong>Background: </strong>Envafolimab is a novel immune checkpoint inhibitor (ICI) with several advantages due to its subcutaneous administration. Phases I and II randomized controlled trials have demonstrated promising efficacy in treating colorectal and gastric cancer. However, the safety and efficacy of Envafolimab in patients with advanced lung cancer remain to be investigated.</p><p><strong>Methods: </strong>This retrospective, multicenter, open-label, single-arm cohort study examined real-world medical data from patients treated at four medical centers to assess the safety and efficacy of Envafolimab in treating patients with advanced lung cancer. The primary safety outcome was Envafolimab-related treatment-emergent adverse events (TEAEs) and immune-related adverse events (irAEs). The primary efficacy outcomes included overall survival (OS) and progression-free survival (PFS). Then, the relationship between clinical parameters and prognosis was investigated using univariate and multivariate regression analyses. Furthermore, the impact of tumor EGFR driver mutation status and PD-L1 expression on prognosis was explicitly explored in patients with nonsmall-cell lung cancer (NSCLC).</p><p><strong>Results: </strong>The cohort comprised 58 patients with a median follow-up time of 8.3 months (from March 1, 2022, to March 7, 2024). Envafolimab-related TEAEs and irAEs were observed in 53.4% and 27.6% of patients, respectively. No specific clinical factors were identified as being associated with irAEs. The median OS was 8.5 months (95% confidence interval [CI] 6.2-10.8), and the median PFS was 6.1 months (95% CI 3.8-8.3). For 47 patients with NSCLC, factors including ECOG PS > 2 (HR: 2.91, p = 0.015), Stage IV tumor (HR: 3.43, p = 0.043), and nonfirst-line Envafolimab treatment (HR: 3.27, p = 0.026) were associated with poor prognosis.</p><p><strong>Conclusion: </strong>Envafolimab demonstrates a tolerable safety profile and favorable efficacy. With its subcutaneous formulation, Envafolimab shows promising potential for treating advanced lung cancer.</p>","PeriodicalId":23338,"journal":{"name":"Thoracic Cancer","volume":"16 12","pages":"e70101"},"PeriodicalIF":2.3,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144310496","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response Letter to \"Management of Chylothorax Following Thoracic Surgery\" by Busetto et al.","authors":"Lionel Arrivé","doi":"10.1111/1759-7714.70103","DOIUrl":"10.1111/1759-7714.70103","url":null,"abstract":"","PeriodicalId":23338,"journal":{"name":"Thoracic Cancer","volume":"16 11","pages":"e70103"},"PeriodicalIF":2.3,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12138036/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144226866","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chinese Expert Consensus on Leptomeningeal Metastases of Lung Cancer.","authors":"Gen Lin, Yongsheng Wang, Tao Xin, Ding Zhang, Qiuyu Zhang, Yangsi Li, Yudan Chi, Yun Fan, Anwen Liu, Haipeng Xu, Liang Shi, Longfeng Zhang, Qian Miao, Xiaobin Zheng, Lijun Li, Kaijia Zhou, Qiwei Yao, Zihua Zou, Kang Miao, Yaping Hong","doi":"10.1111/1759-7714.70088","DOIUrl":"10.1111/1759-7714.70088","url":null,"abstract":"<p><p>Lung cancer patients with leptomeningeal metastases (LMs) suffer from severe clinical symptoms, poor quality of life, narrow diagnostic and therapeutic time windows, low response to standard treatments, short survival periods, and poor prognoses. At present, there is a lack of precise diagnosis and treatment pathways and relevant consensus for LMs of lung cancer. In order to better guide the clinical diagnosis and treatment of LMs of lung cancer in an early, reasonable, and safe way, the experts of the Neurological Tumor Specialist Committee of the Chinese Society of Clinical Oncology (CSCO) have formulated this consensus based on the actual diagnosis and treatment of LMs of lung cancer in China, with reference to the latest research data, relevant guidelines and consensus, and the experts' clinical experience, as well as the results of experts' polling on the pre-set issues of LMs. The consensus focuses on diagnosing LMs, stratified management, efficacy evaluation systems, treatment strategies, common complications, and palliative care. It gives recommendations in each of the five aspects to provide clinicians with suggestions and references for diagnosing and treating LMs in lung cancer.</p>","PeriodicalId":23338,"journal":{"name":"Thoracic Cancer","volume":"16 11","pages":"e70088"},"PeriodicalIF":2.3,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12145986/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144249799","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optimizing Pre-Operative Clinical Staging in Resectable Non-Small Cell Lung Cancer (NSCLC): A Retrospective Cohort Study.","authors":"E Samuel, C Thomas, C Thompson, E Paul, M Cherk, S Ellis, M Siemienowicz, S Tissera, U Samankula, S Scholz, L Zhang, J Grewal, J Cox, C Yu, G Adabi, D Keating, J Taverner, J Gooi, S Wayne, J Zalcberg, R G Stirling","doi":"10.1111/1759-7714.70108","DOIUrl":"https://doi.org/10.1111/1759-7714.70108","url":null,"abstract":"<p><strong>Background: </strong>Accurate pre-operative clinical staging is essential for guiding treatment in resectable non-small cell lung cancer (NSCLC). Discrepancies between clinical and pathological staging raise concerns about treatment appropriateness. This study aimed to assess staging accuracy, identify predictors of discordance, and evaluate survival implications.</p><p><strong>Methods: </strong>We conducted a retrospective cohort study of Stage I-IIIA NSCLC patients who underwent surgical resection in Melbourne, Australia, between 2011 and 2020. Clinical staging was based on CT, PET, and nodal evaluation; pathological staging was based on surgical histology. The primary outcome was concordance between clinical (cTN) and pathological (pTN) stage. Multivariable logistic and Cox regression models evaluated predictors of discordance and survival.</p><p><strong>Results: </strong>Among 221 patients, 58% had concordant clinical and pathological staging. Discordance occurred in 42% of cases-23.9% were upstaged and 17.2% downstaged. N-stage concordance was associated with female sex, tumor histology, SUV max, and CT-to-surgery interval. Nodal discordance independently predicted worse survival (HR 0.43, 95% CI: 0.24-0.77; p = 0.01).</p><p><strong>Conclusions: </strong>Substantial discrepancies exist between clinical and pathological staging in resectable NSCLC. Nodal stage discordance is an independent predictor of mortality and highlights the need for improved pre-operative staging strategies to ensure guideline-concordant care.</p>","PeriodicalId":23338,"journal":{"name":"Thoracic Cancer","volume":"16 11","pages":"e70108"},"PeriodicalIF":2.3,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144302942","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic Impact of Tumor Solid Components in Stereotactic Body Radiotherapy for Clinical Stage Tis-1N0M0 Lung Cancer.","authors":"Junki Fukuda, Hiroshi Doi, Atsushi Kono, Takaya Inagaki, Naoko Ishida Hamazawa, Saori Tatsuno Imamura, Takuya Uehara, Masahiro Inada, Kiyoshi Nakamatsu, Makoto Hosono, Kazunari Ishii, Yukinori Matsuo","doi":"10.1111/1759-7714.70110","DOIUrl":"https://doi.org/10.1111/1759-7714.70110","url":null,"abstract":"<p><strong>Purpose: </strong>This study aimed to assess the potential of prognostic factors including consolidation tumor ratio (CTR) on treatment outcomes in patients with clinical stage 0-IA non-small cell lung cancer (NSCLC) undergoing stereotactic body radiotherapy (SBRT).</p><p><strong>Methods: </strong>The analysis included data of 63 patients with 67 lesions of clinical stage 0-IA NSCLC treated with SBRT. According to the Union for International Cancer Control 8th edition, the following tumor stages were observed: Tis, 3; T1mi, 2; T1a, 11; T1b, 29; and T1c, 22. The prescribed dose was 48 (range, 42-52) Gy in four fractions.</p><p><strong>Results: </strong>The median follow-up was 29.3 (range: 2.4-120.5) months. The five-year local control (LC), overall survival, and progression-free survival (PFS) rates were 89.4%, 60.3%, and 40.5%, respectively. Squamous cell carcinoma (Sq) and D_max < 125 Gy_BED10 for planning target volume (PTV) were associated with a worse LC (p = 0.001 and 0.017, respectively). Patients with Sq, T1b-c, CTR > 0.25, PTV ≥ 30 cm³ tumors were associated with worse PFS than those with non-Sq, ≤ cT1a, CTR ≤ 0.25, PTV < 30 cm³ tumors (p = 0.049, 0.004, 0.038, and 0.004, respectively). No recurrences, metastases, or deaths were found in patients with CTR ≤ 0.25 (n = 5).</p><p><strong>Conclusion: </strong>In patients with stage 0-IA lung cancer treated with SBRT, tumors classified as ≤ T1a showed a better PFS than T1b-c. NSCLC with a low CTR of ≤ 0.25 seemed to have a low risk of recurrence after SBRT.</p>","PeriodicalId":23338,"journal":{"name":"Thoracic Cancer","volume":"16 11","pages":"e70110"},"PeriodicalIF":2.3,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144302943","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Successful Treatment of HER2 V659E Mutation-Positive Lung Adenocarcinoma With Trastuzumab Deruxtecan: A Case Report.","authors":"Mariko Nishihara, Yuki Shinno, Yoshihiro Masui, Ken Masuda, Yuji Matsumoto, Yusuke Okuma, Tatsuya Yoshida, Yasushi Goto, Hidehito Horinouchi, Noboru Yamamoto, Yuichiro Ohe","doi":"10.1111/1759-7714.70100","DOIUrl":"10.1111/1759-7714.70100","url":null,"abstract":"<p><p>A 67-year-old patient with metastatic lung adenocarcinoma harboring a HER2 V659E mutation received trastuzumab deruxtecan (T-DXd) as second-line treatment. The V659E mutation is a rare alteration located in the transmembrane domain of HER2. The antitumor effect observed in this patient was comparable to that reported in a previous phase 2 trial, in which most patients had mutations in the kinase domain. Here, we present the detailed clinical course and discuss the findings from a molecular biological perspective.</p>","PeriodicalId":23338,"journal":{"name":"Thoracic Cancer","volume":"16 11","pages":"e70100"},"PeriodicalIF":2.3,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12138039/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144226867","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Case of Duodenal Metastasis From Malignant Pleural Mesothelioma Diagnosed by Gastrointestinal Endoscopy Following Progressive Anemia During Salvage Chemotherapy.","authors":"Naruhiko Ichiyama, Hiromichi Yamane, Takako Saitou, Masafumi Miura, Ayaka Mimura, Yoko Kosaka, Tatsuyuki Kawahara, Yasunari Nagasaki, Nobuaki Ochi, Hidekazu Nakanishi, Hideyo Fujiwara, Nagio Takigawa","doi":"10.1111/1759-7714.70098","DOIUrl":"10.1111/1759-7714.70098","url":null,"abstract":"<p><p>Malignant pleural mesothelioma (MPM) primarily progresses through direct invasion into the lung and pleura and is a refractory tumor in which asbestos exposure is a major underlying factor in most cases. Hematogenous metastasis of MPM is not uncommon in advanced stages, and reports suggest that metastatic sites may impact prognosis. Gastrointestinal metastases, ranging from the stomach to the colon, have been sporadically observed, but metastases to the small intestine and duodenum are exceedingly rare. Here, we report a case in which duodenal metastasis of MPM was endoscopically identified during the patient's lifetime while undergoing salvage chemotherapy following treatment with an immune checkpoint inhibitor and cytotoxic chemotherapy. Given the rarity and clinical significance of such cases, we present this report with a review of the relevant literature.</p>","PeriodicalId":23338,"journal":{"name":"Thoracic Cancer","volume":"16 11","pages":"e70098"},"PeriodicalIF":2.3,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12141785/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144235351","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Suitability of Frozen Pleural Fluid Pellets for Next-Generation Sequencing-Based Driver Gene Testing in Non-Small Cell Lung Cancer.","authors":"Kazuki Nakashima, Kohei Otsubo, Yuko Tsuchiya-Kawano, Hironori Mikumo, Eiji Iwama, Eiji Harada, Isamu Okamoto","doi":"10.1111/1759-7714.70107","DOIUrl":"10.1111/1759-7714.70107","url":null,"abstract":"<p><strong>Background: </strong>Driver gene alterations are increasingly being identified, and multiplex genetic tests have become essential for determining the optimal treatment method for advanced non-small cell lung cancer (NSCLC). Next-generation sequencing (NGS) enables the simultaneous detection of multiple driver gene alterations using nucleic acids extracted from tumor tissue samples. However, obtaining sufficient tumor tissue volume is challenging, and inadequate formalin fixation can lead to the failure of NGS analysis. Malignant pleural effusions can be collected using a simple, minimally invasive technique; however, it remains uncertain whether pleural fluid is a suitable source for detecting driver gene alterations using NGS. This retrospective observational study examined the suitability of fresh-frozen pleural fluid pellets for NGS in clinical practice.</p><p><strong>Methods: </strong>Patients with NSCLC whose frozen pleural fluid pellets were analyzed using the Oncomine Dx Target Test Multi-CDx System between June 2019 and February 2024 were included in the study. The primary endpoint was the success rate of driver gene analysis.</p><p><strong>Results: </strong>In total, 26 patients were enrolled. The success rate for testing alterations in driver genes was 92.3% (24/26), and the detection rate of targetable driver gene alterations was 53.8% (14/26). The median turnaround time from sample submission to result confirmation was 10 days (range 7-19 days).</p><p><strong>Conclusion: </strong>Our findings indicate that frozen pleural fluid pellets are suitable for NGS-based driver gene testing in patients with advanced NSCLC. This approach provides a practical alternative for multigene testing when sufficient tissue is not available.</p>","PeriodicalId":23338,"journal":{"name":"Thoracic Cancer","volume":"16 11","pages":"e70107"},"PeriodicalIF":2.3,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12150351/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144258941","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Case of Pulmonary Basaloid Squamous Cell Carcinoma in a Non-Smoking Female: Case Report and Literature Review.","authors":"Tsukasa Satoh, Watanabe Hiromu, Nakamura Kimie, Mitsui Izumi, Nishikawa Keiichi, Chiba Shigehiro, Kenzo Soejima","doi":"10.1111/1759-7714.70106","DOIUrl":"10.1111/1759-7714.70106","url":null,"abstract":"<p><p>Pulmonary basaloid squamous cell carcinoma (BSCC) is a rare, high-grade subtype of lung squamous cell carcinoma. It predominantly affects elderly male smokers and is usually diagnosed at an advanced stage. Here, we report an early-stage BSCC in a 67-year-old non-smoking female identified during routine health screening. Chest CT revealed a 30-mm mass in the right lower lobe. PET-CT showed mild FDG uptake without lymph node or distant metastasis. Bronchoscopy confirmed malignancy, and thoracoscopic lobectomy with mediastinal lymph node dissection was performed. Gross pathology demonstrated a polypoid tumor protruding into the bronchial lumen. Histologically, the tumor exhibited solid basaloid nests with peripheral palisading and a high nuclear-to-cytoplasmic ratio. Immunohistochemistry showed strong p63 and CK5/6 positivity, with weak focal p40 expression in less than 20% of tumor cells. Ki-67 labeling index was approximately 50%. Neuroendocrine and breast cancer markers were negative. Mosaic p53 positivity was observed, and no actionable mutations were identified via next-generation sequencing. The final diagnosis was primary pulmonary BSCC (pT1cN0M0, Stage IA3). The patient remains recurrence-free 18 months postoperatively without adjuvant therapy. A literature review of 11 representative reports revealed BSCC typically presents in older male smokers at later stages and carries a poor prognosis. This case highlights the potential for BSCC to occur in non-smokers and at early stages, emphasizing the importance of a multidisciplinary diagnostic approach integrating histology, immunohistochemistry, and molecular data.</p>","PeriodicalId":23338,"journal":{"name":"Thoracic Cancer","volume":"16 11","pages":"e70106"},"PeriodicalIF":2.3,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12166377/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144295027","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"First-Line Immune-Combination Therapy for Driver Gene-Negative NSCLC With Brain Metastases: Real-World Outcomes.","authors":"Mengxing You, Lige Wu, Jiayu Liu, Hanqi Yuan, Zihe Wang, Xuezhi Hao, Puyuan Xing, Junling Li","doi":"10.1111/1759-7714.70095","DOIUrl":"10.1111/1759-7714.70095","url":null,"abstract":"<p><strong>Background: </strong>Optimal treatment for driver gene-negative non-small cell lung cancer (NSCLC) with brain metastases (BM) remains unclear, particularly regarding immune checkpoint inhibitor (ICI)-based combinations and local BM therapy. Predictive biomarkers for intracranial efficacy are also undefined.</p><p><strong>Methods: </strong>This retrospective study analyzed driver gene-negative NSCLC patients with BM treated with first-line ICI-based systemic therapy (ICI plus chemotherapy [ICI + CT] or ICI + CT plus bevacizumab [ICI + CT + Bev]) from June 2019 to June 2024. The intracranial progression-free survival (icPFS), progression-free survival (PFS), and overall survival (OS) were compared between treatment groups and by BM local therapy. The PD-L1 tumor proportion score (TPS) expression was evaluated for correlation with intracranial efficacy.</p><p><strong>Results: </strong>A total of 36 patients were enrolled in the study. The intracranial objective response rate (icORR) was 70.6% (ICI + CT) versus 78.6% (ICI + CT + Bev) (p = 0.689), with no significant differences in icPFS, PFS, or OS between the two different first-line systemic regimens (all p > 0.05). Local BM therapy (n = 18) did not improve icPFS and OS (all p > 0.05). Extracranial PD-L1 (TPS ≥ 50%, n = 13) correlated with superior icPFS, PFS, and OS (all p < 0.05) versus PD-L1 TPS < 50%. Multivariate analysis confirmed PD-L1 ≥ 50% as an independent prognostic factor (HR = 0.155; 95% CI, 0.025-0.939; p = 0.042).</p><p><strong>Conclusions: </strong>Adding bevacizumab to first-line ICI-chemotherapy did not enhance survival outcomes. Local treatment for BM did not provide additional survival advantages when combined with first-line ICI-based systemic therapy. Extracranial PD-L1 TPS ≥ 50% predicted improved intracranial efficacy.</p>","PeriodicalId":23338,"journal":{"name":"Thoracic Cancer","volume":"16 11","pages":"e70095"},"PeriodicalIF":2.3,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12120191/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144174042","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}